Estimated risk of cross-infection with Pseudomonas aeruginosa in Danish cystic fibrosis patients.
about
Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patientsOutcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic.Epidemic spread of Pandoraea apista, a new pathogen causing severe lung disease in cystic fibrosis patients.Molecular epidemiology of chronic Pseudomonas aeruginosa airway infections in cystic fibrosis.Infection control in cystic fibrosis.Long-term survival and nutritional data in patients with cystic fibrosis treated in a Danish centreComparison of ribotyping and genome fingerprinting of Pseudomonas aeruginosa isolates from cystic fibrosis patientsTwenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain.Defining routes of airborne transmission of Pseudomonas aeruginosa in people with cystic fibrosis.Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its managementPseudomonas aeruginosa biofilm infections: from molecular biofilm biology to new treatment possibilities.Heterogeneity of Pseudomonas aeruginosa in Brazilian cystic fibrosis patientsComprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis.Pseudomonas aeruginosa and Burkholderia cepacia infection in cystic fibrosis patients treated in Toronto and Copenhagen.Cross-reactive antigens shared by Pseudomonas aeruginosa, Helicobacter pylori, Campylobacter jejuni, and Haemophilus influenzae may cause false-positive titers of antibody to H. pylori.Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection.Early infection and progression of cystic fibrosis lung disease.Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark.Cystic fibrosis. 7. Management of cystic fibrosis in different countries. Cystic fibrosis in Copenhagen.Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis.Effects of segregation on an epidemic Pseudomonas aeruginosa strain in a cystic fibrosis clinic.Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission.Prevention of chronic Pseudomonas aeruginosa infection in people with cystic fibrosis.
P2860
Q24658094-4C82C00A-7D2C-4A2C-90B5-F3D4307EF19FQ33775997-8732E3E2-DE61-486C-AE74-F19E2A85F12BQ34266590-C62BE96C-EDA8-4BEA-A183-FCD00BF1D518Q34500683-3CC9A852-21E8-408B-85A9-0221E2885EBBQ35545544-3AC78820-E191-498B-A453-53D927FA07F4Q36501442-01FD4A38-78F5-4B91-90B9-A28660991A42Q36527531-E668159D-12C7-4166-BF91-277DEC1C3AA9Q37713415-2AE0C213-56CF-49A5-AA0F-A48234B471A2Q37775628-8033BDBF-671E-4E31-BD2A-FB5467327654Q38007627-C61C0404-DCF4-475C-AD70-27755B9A9F7FQ38268531-53D808E2-1133-423C-AE25-4064E34E866EQ39466908-FAC199DE-A9BD-4D35-9916-FB4FC2C58913Q39474739-56687165-6F00-4242-8992-DEE73BA3B635Q39474744-D4FE5EAA-F97B-465F-808F-EBAB63C09123Q39809545-080A9941-2013-48E9-AB9A-A37E96B01C72Q39997040-00AAB405-D34F-46EC-8CED-A0608364879EQ40636854-EBCB5C19-E7ED-46FC-B3CD-742AAF0C18DEQ41145157-BDCD0AD8-4D3C-40F1-8CB1-485EBE329CB5Q41782321-C99942F4-D0DB-40D3-B93A-D5108A1CEE19Q47793000-93BF4F02-D6AD-405E-B246-5A6B1D5CAB98Q47849237-5F331B53-B835-4DA3-8631-6E13F1E2B673Q51669881-F3ABC9A7-F973-4848-AF94-E7703664ACD8Q52847673-C96ADD49-90DA-4254-9B86-6EB5A72FE04F
P2860
Estimated risk of cross-infection with Pseudomonas aeruginosa in Danish cystic fibrosis patients.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh-hant
name
Estimated risk of cross-infect ...... nish cystic fibrosis patients.
@en
Estimated risk of cross-infect ...... nish cystic fibrosis patients.
@nl
type
label
Estimated risk of cross-infect ...... nish cystic fibrosis patients.
@en
Estimated risk of cross-infect ...... nish cystic fibrosis patients.
@nl
prefLabel
Estimated risk of cross-infect ...... nish cystic fibrosis patients.
@en
Estimated risk of cross-infect ...... nish cystic fibrosis patients.
@nl
P2860
P1476
Estimated risk of cross-infect ...... nish cystic fibrosis patients.
@en
P2093
P2860
P304
P356
10.1111/J.1651-2227.1989.TB11099.X
P577
1989-05-01T00:00:00Z